Speaker: Davide Rossi, MD, Experimental Hematology Institute of Oncology Research, Bellinzona, Switzerland
Modern advances in genomics and cancer biology, including the studies of Davide Rossi’s research group, have produced an unprecedented body of knowledge regarding the molecular pathogenesis of mature B-cell tumors. His group is working on the translation of newly discovered genetic lesions into the clinical practice as biomarkers for the refinement of the diagnostic workup, prognostic stratification and treatment of B-cell tumor patients by a) running translational studies aiming at discovering novel markers that can help the early prediction of sustained benefit vs loss of benefit from novel agents treatment in CLL and b) validating the “liquid biopsy” as a diagnostic tool to inform in real time mature B-cell tumor diagnosis, prognostication and treatment monitoring.
Venue: CECAD, Building 69, Lecture hall ground floor, Josef-Stelzmann-Str. 26